Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story. email: <a href= "mailto:econrxpodcast@gmail.com">econrxpodcast@gmail.com</a> Twitter/Instagram: @EconRx LinkedIn: <a href= "http://www.linkedin.com/company/econrx">www.linkedin.com/company/econrx</a> Website: <a href= "https://econrx.libsyn.com/">https://econrx.libsyn.com/</a>

In this show we dive into the business of the US healthcare system. Why are some of my medications covered by insurance but not others? What does it mean for a provider to be "in-network?" Above all, WHERE DO OUR HEALTHCARE DOLLARS GO??! We want to understand and answer these questions, and we want you to come with us on this journey.